趋化因子及其受体在乳腺癌中的研究进展  

Research progress of chemokines and their receptors in breast cancer

作　　者：王婉玉 吕晓希 胡卓伟 刘姗姗 WANG Wan-yu;Lü Xiao-xi;HU Zhuo-wei;LIU Shan-shan(State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院、北京协和医学院药物研究所,天然药物活性物质与功能国家重点实验室,北京100050

出　　处：《药学学报》2021年第6期1521-1531,共11页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金:资助项目(81803604)。

摘　　要：趋化因子是一类具有趋化活性的细胞因子,参与调节机体的免疫应答和炎症反应。它们作为一种多功能介质,不仅影响免疫细胞向肿瘤浸润,在肿瘤的生长、血管生成和侵袭转移等方面也发挥重要作用,是目前肿瘤治疗的重要靶点。本文回顾了趋化因子参与调控的信号通路,分析了趋化因子在乳腺癌发生发展中的作用机制,总结了近年来趋化因子及其受体相关的乳腺癌靶向药物,并对趋化因子在抗乳腺癌治疗中的作用进行了展望。Chemokines are small cytokines with chemotactic activity,they are involved in regulating immune responses and inflammatory responses.In the development of tumors,chemokines are multi-functional mediators that not only affect the infiltration of immune cells into the tumor,but also have an important impact on tumor growth,angiogenesis,invasion,and metastasis.Besides,they are important targets of tumor therapy.Here we review chemokines involved in the regulation of signaling pathways,analyze the mechanism of chemokines in the development of breast cancer,summarize the chemokines targeted drugs for breast cancer in recent years and make a prospect about the role of chemokines in anti-breast cancer therapy.

关 键 词：趋化因子 乳腺癌 信号通路 靶向治疗 

分 类 号：R966[医药卫生—药理学]